Company PresentationJanuary 2014

This presentation has been prepared for informational purposes only and does notpurport to be all-inclusive.

We have based the forward-looking statements on our current expectations andprojections about future events. These forward-looking statements are subject toknown and unknown risks, uncertainties and assumptions about us and ouraffiliate companies. There can be no assurance that such results will be realized andactual results in each case could differ materially from those currently anticipatedin such statements as a result of various factors. BioLight is not under anyobligation to update or correct any future forecasts and/or forecasting statementsto reflect events or circumstances after the date of this presentation.

BioLight makes no express or implied representation or warranty as to theachievement of the forecasts or the accuracy or completeness of the informationcontained herein. BioLight expressly disclaims any and all liability which may bebased on such information, errors therein or omissions therefrom.This presentation does not constitute an offer to sell or the solicitationof an offer to subscribe for or buy or sell securities of BioLight.

Safe Harbor Statement

2

BioLight establishes “clusters” of companies around a defined medical condition.

We invest in, manage and commercialize the innovations of the “cluster” companies.

Our approach addresses the urgent need of improving the declining productivity and

scope of innovations in the healthcare industry, particularly among large players.

In the last couple of years we have established two clusters:

• Ophthalmology through our 100% owned XLVision Sciences

• Cancer diagnostics through our 29% controlling ownership of Micromedic (TASE:

MCTC)

Within each cluster we are able to uniquely create knowledge

synergies, economies of scale and acceleration of best practices,

which provides an attractive profile of risk/return to our investors.

Biomed Clusters - A New Approach to Creating Value

3

Corporate Snapshot

Traded on Tel Aviv Stock Exchange (TASE: BOLT)

Backed by investors with significant biopharmaceutical experience including:

• Israel Makov (20% stake), the former President & CEO of Teva Pharmaceuticals, the

world’s 12th largest pharmaceutical company1

• Dilip Shanghvi (22% stake), the founder and managing director of Sun Pharma, India’s

largest pharmaceutical company by market cap2

• Dan Oren (13% stake), the founder, President & CEO of Dexcel Pharma, the 2nd largest

pharmaceutical manufacturer in Israel3

Sources: 1. ‘current partnering 2013’ 2012 revenue base2. Crisil Ratings3. IATI, Israel Advanced Technology Industries 4

• An opportunity to access, through a single investment, a largeportfolio of products across multiple therapeutic areas

• XLVision Sciences - ophthalmic cluster, directed to globalmarkets that exceed $7 billion

• Micromedic - cancer diagnostics cluster, with a rich portfoliodirected to $45 billion markets

• Numerous value-creating milestones over the next 12 months,including initial commercialization of lead opportunities

• World-renowned management team with track record of industrysuccess

• World-class key shareholders

Investment Highlights

5

Extensive Management Expertise

Israel MakovChairman of the Board• Chairman of Sun Pharmaceuticals (NSE: SUNPHARMA), Given Imaging (Nasdaq: GIVN) and Micromedic Technologies

(TASE: MCTC)• Former President & CEO of Teva Pharmaceuticals - world’s leader in the generic industry among the top 12-global

pharma company• Led Teva, through an aggressive M&A strategy, to become a high growth global company, the leader in generics and

the leader in the MS market

Suzana Nahum-ZilberbergChief Executive Officer• Over 15 years of industry experience• Former VP for Asia and Pacific of Teva Pharmaceutical, lead the penetration of Teva into Japan and China, through JV

agreement with Kowa Pharmaceutical (2008) and the acquisition of Taisho Pharmaceutical (2009) which resulted inTeva becoming the fifth largest generic company in Japan.

• Vice Chairman of Micromedic Technologies (TASE: MCTC)

Itai Bar-NatanChief Financial Officer• Prior to serving as CFO of BioLight and its subsidiaries, worked for Ernst & Young for 10 years in both U.S. and Israel• Vast experience in corporate finance, international corporate tax, fund raising for early stage clients , M&As, IPOs and

secondary capital raising.

6

Leverage knowledgeof a specific medical

condition acrossdifferent approaches and

protocol of treatment(diagnostics, treatment,

devices, etc.)

Each company canutilize an individual

approach in commercialefforts, partnering andfundraising and has its

dedicated team ofresearchers resulting in

separate IP

Single investmentprovides access to a

large portfolio ofproducts across

multiple therapeuticareas

How Our Cluster Approach Benefits Investors

Project 6

Project 5 Project 3

Project 1

Project 2

Project 4

Synergies come fromshared resources,executive talent,

exposure to KOLs andaccess to strategic

partners

7

Shortening time tomarket and maximizing

ROI

Provides the ability toapproach a wideproduct offering

targeting a specificdisease or therapeutic

category

An initial equityinvestment in the cluster

allows for a future right offirst offer

Gains multiple synergiesshared among and between

clusters

Our unique approach toknowledge synergies

enhances innovation andbenefits from the speed

and agility of anentrepreneurial

enterprise

How Our Cluster Approach Benefits Strategic Partners

Project 6

Project 5 Project 3

Project 1

Project 2

Project 4

Keeps the full financialimpact of the program off

P&L

8

Our Ophthalmology Cluster:Glaucoma and Dry Eye Syndrome

9

XLVision Sciences Products

Laser-based treatmentfor Glaucoma surgery

Long-term controlled-releasedrug-delivery implant

platform

A diagnostic testfor Dry Eye Syndrome

IOPtimateTM Eye-DTM TeaRx

10

Laser-assisted surgical device that enables eye surgeons performing an accurate Deep

Sclerectomy Glaucoma Surgery to reduce elevated intra-ocular pressure (IOP) without

penetrating the eyeball

Key Advantages

Safe, minimally invasive laser procedure

Significant long-term reduction of IOP

Low post-operation complication rate

One-time procedure reduces the need for medications

Broad IP protection

Easy to learn and simple to perform

Flexible business model that fits both private and public hospitals

CE mark, Mexico, Israel approvals; China FDA approval expected Q1 2014

Revenue generation begins in 2014

IOPtimateTM Technology - Lowering IOP

11

IOPtimateTM Market Potential

• $500M market potential in the U.S. alone

• ~70M Glaucoma patients worldwide of which ~10M in the U.S.

• ~150K annual trabeculecomy and shunts procedures in the U.S.

• ~250K annual trabeculoplasty procedures in the U.S.

• Estimated procedure reimbursement of $1,000 in the U.S.

Additional:

• Drug treated patients

• Rest of the world markets

• Combination of pay-per-procedure and capital equipment business models to address

different needs in each territory

12Source: Market Scope. 2011 Comprehensive Report on the Global Dry Eye Products Market. St.

Louis, Mo: Market Scope, November 2011

IOPtima Path of Value-Creating Events

2014 2015 2016 2017

Sales in EU and Asia,Clinical Study for the

FDA

Sales in EU and Asia,Clinical Study for the

FDA

Sales in EU and ROWClinical Study for the

FDA

Sales in EU and ROWClinical Study for the

FDA

Sales in EU and ROW -FDA Approval

Sales in EU and ROW -FDA Approval

Commercialization inthe U.S., EU and ROWCommercialization inthe U.S., EU and ROW

13

• December 2009 - Optonol (the ExPress developer) acquired by Alcon for a total amount

of up to $200 million; Alcon paid $180 million in the initial stage of the deal and additional

future milestone payments.

• July 2013 - HOYA led a Series B investment round of $13.4 million in InnFocus, which

develops the MicroShunt™ to treat open angle glaucoma (before phase I trial).

M&A Deals

14

• 90% of treated Glaucoma patients are prescribed with eye drops to lower IOP,yet only 1-in-4 uses drops as prescribed

• Known poor compliance and adherence with eye drops is a major clinicalchallenge

The Solution

• Long-term controlled-release drug through subconjunctival implant to beused as a platform for eye drops

• First indication targets the market leading Glaucoma generic druglatanoprost (Xalatan® by Pfizer)

• Simple in-office procedure

• Long-term testing in rabbits, dogs and monkeys

• Pre-IND discussion paved the way to IND submission in H1 2014

• A broad platform technology

• Patent protection

Eye-DTM Solution - Novel Rx Eye Implant

Thickness 300 m3 mm x 7.5 mm

15

• $3.2B market potential in the U.S. alone

• ~3% of U.S. population suffer from Glaucoma (~10M)

• 2-3M patients are diagnosed

• 2M patients are prescribed with latanaprost

• Implant price estimated at annual of $800 per eye

Additional:

• Glaucoma undiagnosed patients

• Rest of the world markets

• Additional indications including back of the eye

Eye-DTM Market Potential

16Source: American Glaucoma Society

Glaucoma Research Foundation

Eye-DTM Path of Value-Creating Events

Submit INDApplication to FDA

and Phase I/IIaQ2-Q4/2014

Submit INDApplication to FDA

and Phase I/IIaQ2-Q4/2014

2014 2015 2016 2017

Q1-Q3/2015Phase IIb Dose-ranging Study

Q1-Q3/2015Phase IIb Dose-ranging Study

Q4/2015-Q4/2016Phase III

Q4/2015-Q4/2016Phase III

FDA Approval andStart of

Commercialization

FDA Approval andStart of

Commercialization

17

18

• June 2011 - pSivida signed an investment agreement with Pfizer for its latanoprost

bioerodible eye implant. The deal includes $2.3 immediate cash payment, $20 million for an

option to take over the R&D after Phase II and a commitment of $146.6 million in combined

milestone payments and royalties.

• December 2010 - Genentech entered into an agreement with ForSight VISION4 for an

exclusive worldwide rights to the proprietary implantable ocular device for $10M in milestone

payments and royalties.

• October 2007 - QLT has entered into an agreement to acquire ForSight Newco II ocular

punctual plug drug delivery system for $42M.

18

M&A Deals

TeaRx - Diagnostic for Dry Eye Syndrome

• Dry Eye is a multi-parameter syndrome

• More than 100 million patients worldwide, ~20-30 million in the U.S. alone

• Few tests are currently available measuring single parameter related to Dry Eye (Schirmer,

TearLab, InflammaDry)

• Assessment of multiple parameters allows improved diagnosis and treatment

TeaRx is a superior diagnostic tool to detect, select treatment and monitor Dry Eye

Major advantages:

• Easy reading, multiple parameters vs. existing methods

• Executed by any healthcare professional

• Inexpensive and easy to use

• No capital equipment required

19

TeaRx Market Potential

• $2.85B market potential in the U.S. alone

• The TeaRx stick can be used for diagnostics and monitoring

• Reimbursement price per stick is estimated at $16-22

• No device / capital equipment required

• ~60,000 doctors in the U.S. (~25K Ophthalmologists, ~35K Optometrists)

• Each doctor sees an average of 5 patients a day, testing both eyes

• ~250 working days per year

• An average reimbursement of $19

Additional:

• 48% of U.S. adults experience dry-eye-syndrome related symptoms

• Rest of the world markets

• Assistance in Refractive and Cataract surgeries

• Companion diagnostics tool

20Source: The International Council of Ophthalmology

The American Optometric Association

TeaRx Path of Value-Creating Events

2014 2015 2016 2017

Clinical Trials andFirst Regulatory

Filings

Clinical Trials andFirst Regulatory

Filings

FDA and CEApprovals

FDA and CEApprovals CommercializationCommercialization

21

• TearLab (developer of Osmolarity Dry Eye diagnostic kit) - Market cap of $335M with $11.8M

annual sales

• November 2013 - RSP received an FDA approval for the InflammaDry, an MMP9 Dry Eye

diagnostic kit

• June 2013 - Nicox strengthened its ophthalmic portfolio with Immco Dry Eye diagnostics'

proprietary test and received an exclusive North American marketing rights with an option

for the rest of the world.

22

Valuations & M&A Deals

Ophthalmic Peer Company Valuations

Company Symbol Description Revenue(mil)

Market Cap(mil)

Staar Surgical STAA Develops implantable lenses for the eye 69.6$ 600$

TearLab TEAR Commercializing an in-vitro diagnostic testingplatform used to diagnose Dry Eye Syndrome 11.8$ 335$

Nicox SA NICXF Developing therapies and diagnostics toenhance sight 0.4$ 223$

pSivida PSDV Develops drug delivery products for back-of-the-eye diseases 2.2$ 107$

IRIDEX IRIX Provides therapeutic based laser systems forsight-threatening eye diseases 30.9$ 99$

Updated to January 1st, 201423

Our Cancer Diagnostics Cluster

24

Rich Portfolio with Focus on Market Needs

Screening Monitoring DiagnosisPersonalized

Treatment

ColorectalCancer

BreastCancer

BladderCancer

OtherIndications

Colon-MarCarePlex™

Colon-MarCarePlex™

mCRC-Strat™mCRC-Strat™

BRCABRCA

CellDetect®

BladderCellDetect®

BladderCellDetect®

BladderCellDetect®

Bladder

®®Brain

Metastasis(Lung)

BrainMetastasis

(Lung)BRONJBRONJ

CellDetect®

CervicalCellDetect®

Cervical

25

Colon-MarCarePlex ™

mCRC-Strat™

BrainMetastasis

Predictive gene expressionprofiling assay to identify lungcancer patients who are atincreased risk to develop brainmetastasis

The Technologies

A molecular biomarker (RNA)panel for screening advancedadenoma and colorectal cancer(CRC)

Predictive multi-biomarker IHCassay for the stratification ofmetastatic CRC patients eligiblefor anti-EGFR therapy

Bio-Gene

A novel histochemical staining kit foridentification of cervical neoplasia inhistological and cytological samples

A novel histochemical staining kitfor monitoring bladder cancerrecurrence in urine samples

Predictive genetic (SNP) test foridentification of increased risk todevelop BRONJ, a devastating sideeffect following treatment withbisphosphonate drugs

A functional gene expressionprofiling assay to identify carriers ofdeleterious BRCA mutations whoare at increased risk to developbreast and/or ovarian cancer

Technology Description

CellDetect®

Cervical

CellDetect®

Bladder

BRONJ

Technology Description

26

CellDetect®

Bladder

BRONJ

Portfolio of Technologies and Products

Research StageResearch Stage Feasibility StageFeasibility Stage Validation StageValidation Stage Registration &Commercialization

Registration &Commercialization

CellDetect®

Cervical

Bio-Gene

Colon-MarCarePlex™

mCRC-Strat™

BrainMetastasis

27

CellDetect® - An Innovative Platform for Identifying and DiagnosingPre-Cancer and Cancer Cells

PAP Staining CellDetect® Staining

CellDetect® Staining

28

• A histochemical cytology test for identifying cervical cancercells in cervical smear, based on the CellDetect®patent-protected platform technology

• Clinical proof-of-concept for identifying and diagnosing thedisease in cytology samples (sensitivity of 92% and specificityof 80%) offering higher sensitivity over Pap and betterspecificity over HPV tests

• Commercial in China this year

• Strategic collaboration in India with leading oncologyhospital network

• Regulatory approvals in Europe, Israel and China

• ~200 million tests globally per year with multibillion-dollarglobal market

CellDetect® Cervical Cancer

29

• A histo-chemical cytology, non-invasive, accurate and low cost

test for identifying bladder cancer cells in a urine sample

• Clinical trial shows 95% sensitivity and 88% specificity in

detecting bladder cancer cells in urine samples

• Multi-center clinical trial initial results estimated at H1/2014

• US market accounts half million patients performing 3-4

monitoring tests a year, with estimated market size of $200

million and hundreds of millions dollar market potential of

screening market

CellDetect® Bladder Cancer

30

CellDetect® Path of Value-Creating Events

2014 2015 2016

CellDetect®

Cervical CancerCellDetect®

Cervical Cancer

2017

CellDetect®

Bladder CancerCellDetect®

Bladder Cancer

Commercializationin the Chinese

Market

Commercializationin the Chinese

MarketCommercialization in China and Other MarketsCommercialization in China and Other Markets

Validation ClinicalTrial & Registration

Process

Validation ClinicalTrial & Registration

Process

Approval & Launchin EU and U.S.

Markets

Approval & Launchin EU and U.S.

MarketsCommercializationCommercialization

31

CellDetect® Automation

Bladdercancer urine

cytologytest

CirculatingTumor Cells(CTC) blood

test Prostatecancer urine

test

Lung cancersputum test

CellDetect® Platform Roadmap

32

CellDetect®

Platform

Suspensiontechnology

for POCapplications

Cervicalcancer

cytologytest

Identification of increased risk to develop a devastating side effect following treatment

with bisphosphonates

• Product - A novel SNP assay (licensed technology from the University of Florida) that

aims to detect individuals with a unique genetic profile which increases their risk to

develop BRONJ

• Market potential**

• Major Cancers - over 400,000 worldwide cases of metastatic cancer treated with

bisphosphonates with high incidence of BRONJ

• Osteoporosis - ~200 million women with disease (<0.1% reported to develop BRONJ)

• Findings - A clinical trial conducted at University of Florida demonstrated that

multiple myeloma patients positive to the test, harboring the

unique genetic profile, have 10 times the probability of developing BRONJ

• Completing the first stage of the multiple myeloma trial in H1-2014

BRONJ*

* Bisphosphonate Related Osteonecrosis of the Jaw** Source: globocan 2008 33

• Product - A unique functional gene expression test to identify carriers

of harmful BRCA mutations who are at increased risk to develop

breast and/or ovarian cancer

Developed in collaboration with Prof. Tamar Peretz, Head of the

Sharett Institute of Oncology at Hadassah MC and her colleagues

• Market potential - Around 120,000 tests in the US and growing global

market

• Findings - Initial clinical data performed at Hadassah MC showed a

sensitivity of 90% and a specificity of 84% (sample size = 57)

Bio-Gene (BRCA)Identifying Deleterious BRCA Mutations in High-Risk Individuals

34

BioLight:

• Listed Level 1 American Depository Receipts for BioLight - Q1 2014

Ophthalmic Cluster (XLVision Sciences):

• Receive China FDA approval of IOPtimate™ - H1 2014

• Begin sales of IOPtimate™ in select Asian and EU countries, Mexico and Israel - H1 2014

• Submit Investigational New Drug (IND) application for Eye-D™ to U.S. FDA - H1 2014

• Begin phase I, IIa human trials of Eye-D™ - H2 2014

• First regulatory filing for TeaRx - H2 2014

Cancer Diagnostic Cluster (Micromedic):

• Commercial sales in China of CellDetect® for cervical cancer - H1 2014

• Completion of clinical trials for CellDetect® cervical cancer in India and preparation to

commercialization - H2 2014

• Interim results of multi-center clinical trial for CellDetect® bladder cancer recurrence in

urine samples – H1 2014

• Report results of BRONJ predictive genetic test in multiple myeloma patients - H1 2014

2014 Milestones

35

In Summary

36

• BioLight provides an opportunity to access, through a singleinvestment, a large portfolio of products across multipletherapeutic areas

• XLVision Sciences - ophthalmic cluster, directed to globalmarkets that exceed $7 billion

• Micromedic - cancer diagnostics cluster, with a richportfolio directed to $45 billion markets

• Numerous value-creating milestones over the next 12 months,including initial commercialization of lead opportunities

• World-renowned management team with track record ofindustry success

• World-class key shareholders